BioSpace News Archive

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System.

Ichnos Sciences Inc. today announced the selection of ISB 2001, its first TREAT 1 trispecific antibody as its next candidate to move into clinical development.

Outlook Therapeutics, Inc. announced that Russ Trenary, President & Chief Executive Officer of Outlook Therapeutics will participate in the Virtual Investor CEO Spotlight on Wednesday, May 11, 2022 at 1:00 PM ET.

Allogene Therapeutics, Inc. announced that the San Francisco Business Times and the Silicon Valley Business Journal ranked Allogene as the highest rated biotechnology company – and 12th company overall – on the 2022 Best Places to Work in the Bay Area list in the large company category.

Acer Therapeutics Inc. today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its pivotal Phase 3 DiSCOVER.

Longeveron Inc. today announced that the Company will release its first quarter 2022 financial results on Friday, May 13, 2022 before the open of the U.S. financial markets.

Delcath Systems, Inc. announced the acceptance of a poster presentation at the upcoming American Society of Clinical Oncology 2022 Annual Meeting, to be held in-person on June 3-7, 2022, in Chicago, Illinois.

Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at the 2022 American Urological Association Annual Meeting taking place at the New Orleans Ernest N. Morial Convention Center in New Orleans May 13-16, 2022.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, announced the poster presentation of a substantial survival benefit of AllocetraTM combined with immune checkpoint inhibition in a preclinical mesothelioma study at the International Society of Cell and Gene Therapy Annual 2022 Meeting.

The US Patent Office (USPTO) has granted HepaTx patent number 11291691 covering the company’s technology to manufacture hepatocyte-like cells to treat liver disease.